UB Paderborn / Katalog / Suche / in CDI

1 – 19 von 19

Sortiert nach

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD5-03-PD5-03

2020

Link zum Volltext

Verfügbarkeit prüfen

Role of the polarity determinant crumbs in suppressing mammalian epithelial tumor progression

Cancer research (Chicago, Ill.), 2008-06, Vol.68 (11), p.4105-4115

2008

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT069-CT069

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS12-01-PS12-01

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.OT-30-01-OT-30-01

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS1-02-GS1-02

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT073-CT073

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-09-05: Low estrogen receptor positive (1-10%) breast cancer prevalence, treatment patterns and prognosis: A single institution’s experience in Korea

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P2-P2-09-05

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS1-01-GS1-01

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD14-04: Contribution of tumor and immune cells to PD-L1 as a predictive biomarker in triple-negative breast cancer (TNBC): Analysis from KEYNOTE-119

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD14-04-PD14-04

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD14-07-PD14-07

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.GS3-01-GS3-01

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3545: Autophagy inhibition as a therapeutic strategy in cancer

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3545-3545

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.LB-225-LB-225

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-138: Autophagy regulator BECN1 acts as a context-dependent tumor suppressor opposing parity-associated and WNT1-driven mammary tumorigenesis

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.LB-138-LB-138

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4261: Prospective next generation sequencing (NGS) of rare or poor prognosis cancers

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4261-4261

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.S1-S1-09

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3777: Autophagy and HER2 interaction in mammary tumorigenesis

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3777-3777

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3513: Hydroxychoroquine (HCQ) modulates autophagy in melanoma: preliminary results of a phase 0 trial in patients with resectable melanoma

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3513-3513

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 19 von 19

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Zeitschrift / SerieCancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(19)

Sprache

Englisch
(19)
Japanisch
(2)

Erscheinungsjahr

n.n

Kollektion

Menü

Weitere Dienste

Einstellungen

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Role of the polarity determinant crumbs in suppressing mammalian epithelial tumor progression

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Abstract P2-09-05: Low estrogen receptor positive (1-10%) breast cancer prevalence, treatment patterns and prognosis: A single institution’s experience in Korea

Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses

Abstract PD14-04: Contribution of tumor and immune cells to PD-L1 as a predictive biomarker in triple-negative breast cancer (TNBC): Analysis from KEYNOTE-119

Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086

Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer

Abstract 3545: Autophagy inhibition as a therapeutic strategy in cancer

Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086

Abstract LB-138: Autophagy regulator BECN1 acts as a context-dependent tumor suppressor opposing parity-associated and WNT1-driven mammary tumorigenesis

Abstract 4261: Prospective next generation sequencing (NGS) of rare or poor prognosis cancers

Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer

Abstract 3777: Autophagy and HER2 interaction in mammary tumorigenesis

Abstract 3513: Hydroxychoroquine (HCQ) modulates autophagy in melanoma: preliminary results of a phase 0 trial in patients with resectable melanoma

Aktive Filter

Suchergebnisse filtern